Bone fractures among postmenopausal patients with endocrine-responsive early breast cancer treated with 5 years of letrozole or tamoxifen in the BIG 1-98 trial

Annals of Oncology

Volumn 20, Issue 9, 2009, Pages 1489-1498

  Rabaglio, Manuela ^a   Sun, Z ^b   Price, K N ^c   Castiglione Gertsch, M ^d   Hawle, H ^d   Thurlimann B ^e   Mouridsen, H ^f   Campone, M ^g   Forbes, J F ^h   Paridaens, R J ⁱ   Colleoni, M ^j   Pienkowski, T ^k   Nogaret, J M ^l   Lang I ^m   Smith, I ⁿ   Gelber, R D ^o   Goldhirsch, A ^j,p   Coates, A S ^q  

^a UNIVERSITY OF BERN   (Switzerland)

^b DANA FARBER CANCER INSTITUTE   (United States)

^c FRONTIER SCIENCE AND TECHNOLOGY RESEARCH FOUNDATION   (United States)

^d IBCSG Coordinating Center   (Switzerland)

^e CANTONAL HOSPITAL ST GALLEN   (Switzerland)

^f Rigshospitalet   (Denmark)

^g FNCLCC   (France)

^h UNIVERSITY OF NEWCASTLE   (Australia)

ⁱ UNIVERSITY HOSPITALS LEUVEN   (Belgium)

^j EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^k INSTITUTE OF ONCOLOGY   (Poland)

^l JULES BORDET INSTITUTE   (Belgium)

^m NATIONAL INSTITUTE OF ONCOLOGY   (Hungary)

ⁿ ROYAL MARSDEN HOSPITAL   (United Kingdom)

^o HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^p ONCOLOGY INSTITUTE OF SOUTHERN SWITZERLAND   (Switzerland)

^q UNIVERSITY OF SYDNEY   (Australia)

more..

Author keywords

Aromatase inhibitor; Bone fracture; Hormonal therapy; Letrozole; Tamoxifen

Indexed keywords

LETROZOLE; TAMOXIFEN;

ADULT; AGE; ANKLE FRACTURE; ARTICLE; ATTRIBUTABLE RISK; BREAST CANCER; CANCER ADJUVANT THERAPY; CLAVICLE FRACTURE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; EARLY CANCER; FEMALE; FEMUR FRACTURE; FRACTURE; HORMONE SUBSTITUTION; HUMAN; HUMERUS FRACTURE; INCIDENCE; MAJOR CLINICAL STUDY; MULTICENTER STUDY; PELVIS FRACTURE; PHASE 3 CLINICAL TRIAL; POSTMENOPAUSE; POSTMENOPAUSE OSTEOPOROSIS; PRIORITY JOURNAL; RADIUS FRACTURE; RIB FRACTURE; RISK BENEFIT ANALYSIS; RISK FACTOR; SMOKING; SPINE FRACTURE; TIBIA FRACTURE; TIME; ULNA FRACTURE; WRIST FRACTURE;

EID: 69849115729     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdp033     Document Type: Article

References (24)

1. Geisler J, Ekse D, Helle H et al. An optimised, highly sensitive radioimmunoassay for the simultaneous measurement of estrone, estradiol and estrone sulfate in the ultra-low range in human plasma samples. J Steroid Biochem Mol Biol 2008; 109: 90-95.
2. Dixon JM, Renshaw L, Young O et al. Letrozole suppresses plasma estradiol and estrone sulphate more completely than anastrozole in postmenopausal women with breast cancer. J Clin Oncol 2008; 26: 1671-1676.
3. Powles TJ, Hickish T, Kanis JA et al. Effect of tamoxifen on bone mineral density measured by dual-energy x-ray absorptiometry in healthy premenopausal and postmenopausal women. J Clin Oncol 1996; 14: 78-84.
4. BIG 1-98 Collaborative Group: A comparison of letrozole and tamoxifen in postmenopausal women with early breast cancer. N Engl J Med 2005; 353: 2747-2757.
5. Baum M, Budzar AU, Cuzick J et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: First results of the ATAC randomised trial. Lancet 2002; 359: 2131-2139.
6. Coombes RC, Hall E, Gibson LJ et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 2004; 350: 1081-1092.
7. Jakesz R, Jonat W, Gnant M et al. Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: Combined results of ABCSG trial 8 and ARNO 95 trial. Lancet 2005; 366: 455-462.
8. Coates AS, Keshaviah A, Thurlimann B et al. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: Update of study BIG 1-98. J Clin Oncol 2007; 25: 486-492.
9. Coleman RE, Banks LM, Girgis SI et al. Skeletal effects of exemestane on bonemineral density, bone biomarkers, and fracture incidence in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES): A randomised controlled study. Lancet Oncol 2007; 8: 119-127.
10. Jones SE, Cantrell J, Vukelja S et al. Comparison of menopausal symptoms during the first year of adjuvant therapy with either exemestane or tamoxifen in early breast cancer: Report of a tamoxifen exemestane adjuvant multicenter trial substudy. J Clin Oncol 2007; 25: 4765-4771.
11. Winer EP, Hudis C, Burstein HJ et al. American Society of Clinical Oncology Technology Assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: Status report 2004. J Clin Oncol 2005; 23: 619-629.
12. Boccardo F, Rubagotti A, Puntoni M et al. Switching to anastrozole versus continued tamoxifen treatment of early breast cancer: Preliminary results of the Italian tamoxifen anastrozole trial. J Clin Oncol 2005; 23: 5138-5147.
13. Goss PE, Ingle JN, Martino S et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 2003; 349: 1793-1802.
14. Perez EA, Josse RG, Pritchard KI et al. Effect of letrozole versus placebo on bone mineral density in women with primary breast cancer completing 5 or more years of adjuvant tamoxifen: A companion study to NCIC CTG MA.17. J Clin Oncol 2006; 24: 3629-3635.
15. Goss PE, Ingle JN, Pater JL et al. Late extended adjuvant treatment with letrozole improves outcome in women with early-stage breast cancer who complete 5 years of tamoxifen. J Clin Oncol 2008; 26: 1948-1955.
16. Chien AJ, Goss PE. Aromatase inhibitors and bone health in women with breast cancer. J Clin Oncol 2006; 24: 5305-5312.
17. Agresti A. Exact inference for categorical data: Recent advances and continuing controversies. Stat Med 2001; 20: 2709-2722.
18. Bonetti M, Gelber RD. A graphical method to assess treatment covariate interactions using the Cox model on subsets of the data. Stat Med 2000; 19: 2595-2609.
19. Bonetti M, Gelber R. Covariates and the pattern of treatment effects in clinical trials. Biostatistics 2004; 5: 465-481.
20. Cox DR. Regression models and life tables. J R Stat Soc B 1972; 34: 187-220.
21. Gray RJ. A class of k-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat 1988; 16: 1141-1154.
22. Forbes JF, Cuzick J, Buzdar A et al. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol 2008; 9: 45-53.
23. Goss PE, Ingle JN, Martino S et al. Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: Updated findings from NCIC CTG MA.17. JNCI Cancer Spect 2005; 97: 1262-1271.
24. Hadji P, Body JJ, Aapro MS et al. Practical guidance for the management of aromatase inhibitor-associated bone loss. Ann Oncol 2008; 19: 1407-1416.